Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: The EMPAR study

Circulation

Volumn 94, Issue 7, 1996, Pages 1553-1560

  Cairns, John A ^a,e   Gill, John ^a   Morton, Brian ^b   Roberts, Robin ^a   Gent, Michael ^a   Hirsh, Jack ^a   Holder, Douglas ^a   Finnie, Keith ^c   Marquis, Jean François ^b   Naqvi, Salim ^d   Cohen, Eric ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

angioplasty; coronary disease; fish oils; heparin; restenosis

Indexed keywords

ENOXAPARIN; FISH OIL; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 10144253709     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.7.1553     Document Type: Article

References (40)

1. Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB, McAllister BD, Smith SC, Ullyot DJ. ACC/AHA Task Force report: guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 1993;22:2033-2054.
2. Holmes DR, Schwartz RS, Webster MW. Coronary restenosis: what have we learned from angiography? J Am Coll Cardiol. 1991;17:14B-22B.
3. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issues. In: Topol EJ. Textbook of Interventional Cardiology. Philadelphia, Pa: WB Saunders Co; 1994:415-435.
4. Goodnight SH, Cairns JA, Fisher M. Fitzgerald GA. Assessment of the therapeutic use of n-3 fatty acids in vascular disease and thrombosis. Chest. 1992;102:374S-384S.
5. Burr ML, Gilbert JF, Holliday RM, Elwood PC, Fehily AM, Rogers S, Sweetnam PM, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2:757-761.
6. De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin J-L, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linoleic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454-1459.
7. Leaf A, Weber P. Cardiovascular effects of n-3 fatty acids. N Engl J Med. 1988;318:549-557.
8. Weiner BH, Ockene IS, Levine PH, Cuenoud HF, Fisher M, Johnson BF, Daoud AS, Jarmolych J, Hosmer D, Johnson MH, Natale A, Vaudreuil C, Hoogasian JJ. Inhibition of atherosclerosis by cod liver oil in a hyperlipidemic swine model. N Engl J Med. 1986;315:841-846.
9. Dehmer GJ, Popma JJ, van der Berg EK, Eichhorn EJ, Prewitt JB, Campbell WB, Jennings L, Willerson JT, Schmitz JM. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med. 1988;319:733-740.
10. Grigg LE, Kay TWH, Valentine PA, Larkins R, Flower DJ, Manolas EG, O'Dea K, Sinclair AJ, Hopper JL, Hunt D. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. J Am Coll Cardiol. 1989;13:665-672.
11. Reis GJ, Boucher TM, Sipperly ME, Silverman DI, McCabe CH, Baim DS, Sacks FM, Grossman W, Pasternak RC. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet. 1989;2:177-181.
12. Milner MR, Gallino RA, Leffingwell A, Pichard AD, Brooks-Robinson S, Rosenberg J, Little T, Lindsay J. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1989;62:294-299.
13. Slack JD, Pinkerton CA, Van Tassel J, Orr CM, Scott M, Allen B, Vasser WK. Can oral fish oil supplement minimize restenosis after percutaneous transluminal angioplasty? J Am Coll Cardiol. 1987;9:64A. Abstract.
14. Peto R. Clinical trial methodology. Biomedicine. 1978;28:849-857.
15. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977;265:625-626.
16. Guyton RJ, Rosenberg RD, Clowes AW, Karnovsky MJ, Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res. 1980;46:625-634.
17. Currier JW, Pow TK, Handenschild CC, Minihan AC, Faxon DP. Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J Am Coll Cardiol. 1991;17(suppl B):118B-125B.
18. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
19. Nye ER, Ilsley CDJ, Ablett MB, Sutherland WHF, Robertson MC. Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. Aust N Z J Med. 1990;20:549-552.
20. Bairati I, Roy L, Meyer F, Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation. 1992;85:950-956.
21. Kaul U, Sanghvi S, Bahl VK, Dev V, Wasir HS. Fish oil supplements for prevention of restenosis after coronary angioplasty. Int J Cardiol. 1992;34:87-93.
22. Bellamy CM, Schofield PM, Faragher EB, Ramsdale DR. Can supplementation of diet with omega-3 polyunsaturated fatty acids reduce coronary angioplasty restenosis rate? Eur Heart J. 1992;13:1626-1631.
23. Knapp HR, Reilly IAG, Allesandrini P, FitzGerald GA. In vivo indexes of platelet and vascular function during fish oil administration in patients with atherosclerosis. N Engl J Med. 1986;314:937-942.
24. Leaf A, Jorgensen MB, Jacobs AK, Cote G, Schoenfeld DA, Jeheer J, Weiner BH, Slack JD, Kellet MA, Raizner AE, Weber PC, Mahrer PR, Rossouw JE. Do fish oils prevent restenosis after coronary angioplasty? Circulation. 1994;90:2248-2257.
25. Schmidt T, Tebbe U, Schrader J, Brune S, Kreuzer H. Pharmacological therapy after coronary angioplasty: early experience with low molecular weight heparin for prophylaxis of reocclusion. Klin Wochenschr. 1990;68:294.
26. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB III. Effect of 18 to 24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J. 1989;117:777-782.
27. De Vries CJ, Michels HR, Emmanuelsson M, El Gamel MIH. Does administration of low molecular weight heparin after angioplasty affect restenosis? Eur Heart J. 1991;12(suppl):386.
28. Lehrman KG, Doria RJ, Feuer AJM, Hall PX, Hoang DT. Paradoxical increase in restenosis rate with chronic heparin use: final results of a randomized trial. J Am Coll Cardiol. 1991;17:181A. Abstract.
29. Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB, Ohman M, and the ERA Investigators. Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparine Restenosis (ERA) Trial. Circulation. 1994;90:908-914.
30. Brack MJ, Ray S, Chauhan A, Fox J, Hubner PJB, Schofield P. Harley A, Gershlick AH, for the SHARP Investigators. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) Trial: results of a multicenter randomized trial investigating the effects of high dose un-fractionated heparin in angiographic restenosis and clinical outcome. J Am Coll Cardiol. 1995;26:947-954.
31. Castellot JJ, Favreau LV, Karnovsky MJ, Rosenberg RD. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin: possible role of a platelet endoglycosidase. J Biol Chem. 1982;257;1256-1260.
32. Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Ore Res. 1987;61:246-300.
33. Castellot JJ Jr, Cochran DL, Karnovsky MJ. Effect of heparin on vascular smooth muscle cells, I: cell metabolism. J Cell Physiol. 1985;124:21-28.
34. Reilly CF, Fritze LMS, Rosenberg RD. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol. 1986;129:11-19.
35. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mantner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol, 1995;26:313-318.
36. Geary RL, Koyama N, Wang TW, Vergel S, Clowes AW. Failure of heparin to inhibit intimal hyperplasia in injured baboon arteries: the role of heparin-sensitive and -insensitive pathways in the stimulation of smooth muscle cell migration and proliferation. Circulation. 1995;91:2972-2981.
37. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelson H, Marko J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M-A, for the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
38. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein BS, Fish D, Columbo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994:331:496-501.
39. Maresta A, Balucelli M, Cantini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Preti PAM, Repetto S, DeServi S, Varani E, for the STARC Investigators. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: results of the randomized, double-blind STARC study. Circulation. 1994;90:2710-2715.
40. Hillegass WB, Ohman EM, Leimberger JD, Califf RM. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol. 1994;73:835-839.